ENDRA Life Sciences Issued Additional U.S. and Chinese Patents for its TAEUS® System
May 10 2022 - 8:00AM
Business Wire
Four newly issued patents bolster protection
for TAEUS® with 46 patents issued globally
New U.S. patent expands potential licensing
opportunities in data management
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer
of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the
issuance of four new patents, two in the U.S. and two in China.
ENDRA’s intellectual property portfolio now includes 90 assets,
including 46 issued patents worldwide providing protection for the
TAEUS system with its novel hybrid ultrasound and thermoacoustic
imaging technology. One of the newly issued U.S. patents, which
protects the ability to transfer data without an internet
connection, expands potential licensing opportunities for the
company.
The following four patents, strengthening the TAEUS system’s
proprietary position, were issued:
- U.S. Patent No. 11314617 (the “‘617 patent”), titled “Methods
and Systems for Exchange of Equipment Performance Data,” is ENDRA’s
first patent that protects its proprietary method and system for
acquiring, analyzing, and sharing data in the cloud. Although this
technology was developed for the TAEUS system, it has broad
applicability within the healthcare industry and as such,
represents an additional licensing opportunity. The company has
filed another application to complement the ‘617 patent, which is
expected to form the keystone of a patent family.
- U.S. Patent No. 11304606, titled “Method and System for
Enhancing RF Energy Delivery During Thermoacoustic Imaging,”
relates to optimizing the thermoacoustic energy source, a
radiofrequency emitter, to provide a stronger and clearer signal
that improves thermoacoustic measurements.
- Chinese Patent No. ZL 2019 8 00868104 (the “‘104 patent”),
titled “Method and System for Monitoring Tissue Temperature,”
relates to a novel method and system for monitoring tissue
temperature during surgical procedures. ENDRA expects its TAEUS
system to be effective for both thermotherapy and cryotherapy
procedures. The ‘104 patent is linked to its parent, U.S. Patent
No. 10631734B1.
- Chinese Patent No. ZL 2019 8 00859567 (the “‘567 patent”),
titled “Method and System for Estimating Fractional Fat Content of
an Object of Interest,” relates to a novel method for determining
the fractional fat content of an object, such as a person’s liver.
This method utilizes a radiofrequency applicator that is a critical
component of the TAEUS system. The ‘567 patent is linked to its
parent, U.S. Patent No. 11051699B2.
“These newly issued patents further bolster our proprietary
position for the TAEUS system in two key geographies and increase
our intellectual property portfolio to 90 assets, with 46 issued
patents globally," stated ENDRA's Chairman and Chief Executive
Officer Francois Michelon. "Although we have focused our efforts to
protect our novel TAEUS system, the most recently issued U.S.
patent broadly covers the transfer of equipment performance data.
Consequently, we intend to explore licensing opportunities with
other healthcare equipment manufacturers seeking novel and
efficient data management technologies, as an additional source of
revenue for the company.”
About ENDRA Life Sciences
Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced
UltraSound (TAEUS®), a ground-breaking technology being developed
to visualize tissue like MRI, but at 1/50th the cost and at the
point of patient care. TAEUS® is designed to work in concert with
400,000 cart-based ultrasound systems in use globally today. TAEUS®
is initially focused on the measurement of fat in the liver as a
means to assess and monitor Non-Alcoholic Fatty Liver Disease
(NAFLD) and inflammation (NASH), chronic liver conditions that
affect over one billion people globally, and for which there are no
practical diagnostic tools. Beyond the liver, ENDRA is exploring
several other clinical applications of TAEUS®, including
visualization of tissue temperature during energy-based surgical
procedures. For more information, please visit
www.endrainc.com.
Forward-Looking Statements
All statements in this press release that are not based on
historical fact are "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements, which
are based on certain assumptions and describe our future plans,
strategies and expectations, can generally be identified by the use
of terms such as “approximate,” "anticipate," “attempt,” "believe,"
"could," "estimate," "expect," “forecast,” “future,” "goal,"
“hope,” "intend," "may," "plan," “possible,” “potential,”
“project,” "seek," "should," "will," “would,” or other comparable
terms (including the negative of any of the foregoing), although
some forward-looking statements are expressed differently. Examples
of forward-looking statements for ENDRA include, among others:
estimates of the timing of future events and anticipated results of
our development efforts, including the timing for receipt of
required regulatory approvals and product launches; future
financial position and projected costs and revenue; expectations
concerning ENDRA's business strategy; ENDRA’s ability to find and
maintain development partners; market acceptance of ENDRA’s
technology and the amount and nature of competition in its
industry; and ENDRA’s ability to protect its intellectual property.
Forward-looking statements involve inherent risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements as a result of various factors
including, among others: the ability to raise additional capital in
order to continue as a going concern; the ability to obtain
regulatory approvals necessary to sell ENDRA medical devices in
certain markets in a timely manner, or at all; the ability to
develop a commercially feasible technology and its dependence on
third parties to design and manufacture its products; the impact of
COVID-19 on ENDRA’s business plans; the ability to find and
maintain development partners; market acceptance of ENDRA’s
technology and the amount and nature of competition in its
industry; ENDRA’s ability to protect its intellectual property; and
the other risks and uncertainties described in the Risk Factors and
Management’s Discussion and Analysis of Financial Condition and
Results of Operations sections of the Company’s most recent Annual
Report on Form 10-K and in subsequent Quarterly Reports on Form
10-Q filed with the Securities and Exchange Commission. You should
not rely upon forward-looking statements as predictions of future
events. The forward-looking statements made in this press release
speak only as of the date of issuance, and ENDRA assumes no
obligation to update any such forward-looking statements to reflect
actual results or changes in expectations, except as otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220510005316/en/
Irina Pestrikova Senior Director, Finance investors@endrainc.com
www.endrainc.com
Investor Relations: Yvonne Briggs LHA Investor Relations (310)
691-7100 YBriggs@lhai.com
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
ENDRA Life Sciences (NASDAQ:NDRA)
Historical Stock Chart
From Apr 2023 to Apr 2024